Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.

Oncogene · 2018 · PMC6013054 · PMID 29511346

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although bilirubin levels did not decrease significantly, they showed a trend towards reduction at higher doses of MTL-CEBPA treatment ( Fig. 5B ).

also in 53,322 other papers

an increasing trendno p-value reported

Although there was no significant increase in albumin transcript levels at day 12 across all the treated groups, we observed an increasing trend in the MTL-CEBPA treatment group.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.